Sunil Agarwal has sold stock and made no open-market buys since Jan 2016
EVP, Head of Development, CMO at Sana Biotechnology, Inc., and 2 other companies
SEC CIK 0001616640 · Filings on SEC.gov ↗
Companies
Every filing
9 filings since Jan 2016, newest first
Sana Biotechnology, Inc.
EVP, Head of Development, CMO
Juno Therapeutics, Inc.
Pres of R, D
Ultragenyx Pharmaceutical Inc.
Chief Medical Officer
Ultragenyx Pharmaceutical Inc.
Chief Medical Officer
Ultragenyx Pharmaceutical Inc.
Chief Medical Officer
Ultragenyx Pharmaceutical Inc.
Chief Medical Officer
Ultragenyx Pharmaceutical Inc.
Chief Medical Officer
Ultragenyx Pharmaceutical Inc.
Chief Medical Officer
Ultragenyx Pharmaceutical Inc.
Chief Medical Officer
About Sunil Agarwal
Sunil Agarwal, M.D. is a biotechnology executive and physician who served as Executive Vice President, Head of Development and Chief Medical Officer at Sana Biotechnology, Inc., where he was responsible for the company’s overall pipeline strategy and execution, development capabilities, and broader corporate strategy.( He co-founded Sana in 2018 and later helped guide its development organization; Sana announced in 2023 that he would depart after supporting a leadership transition.(
Before Sana, Dr. Agarwal was President of Research and Development at Juno Therapeutics and previously served as Chief Medical Officer and Executive Vice President at Ultragenyx Pharmaceutical, overseeing clinical development, regulatory affairs, biometrics, pharmacovigilance, medical affairs, pharmacology, and toxicology.( Earlier in his career, he held multiple leadership roles at Genentech for more than a decade, including Senior Vice President and Global Head of Clinical Development across ophthalmology, metabolism, neurosciences, immunology, and infectious diseases, and he also worked at MedImmune and Guilford Pharmaceuticals.( Dr. Agarwal earned a B.S. in neurobiology from Cornell University and an M.D. from Tufts University School of Medicine, and completed his residency at Children’s National Medical Center in Washington, D.C.(
Written by Perplexity from public sources.
Filings come from SEC EDGAR. Not investment advice.